Welcome to our dedicated page for Hansa Medical AB news (Ticker: HNSBF), a resource for investors and traders seeking the latest updates and insights on Hansa Medical AB stock.
The HNSBF news page on Stock Titan tracks announcements and developments related to HANSA MEDICAL AB ORD and its underlying company, Hansa Biopharma AB. Hansa Biopharma is a commercial-stage biopharmaceutical company based in Lund, Sweden, focused on rare immunological conditions through an IgG-cleaving enzyme technology platform. News for HNSBF therefore reflects clinical, regulatory, commercial and corporate milestones reported by Hansa Biopharma.
Investors following HNSBF can expect updates on imlifidase, Hansa Biopharma’s first-in-class IgG antibody-cleaving enzyme therapy, and its use in transplantation, autoimmune diseases and gene therapy. Recent communications have included pivotal Phase 3 data from the ConfIdeS trial in highly sensitized kidney transplant patients, Phase 2 results in antibody-mediated rejection after kidney transplantation, and progress in autoimmune indications such as anti-GBM disease and Guillain-Barré Syndrome.
The news flow also covers regulatory and market access decisions for IDEFIRIX (the European trade name for imlifidase) in the desensitization of highly sensitized adult kidney transplant patients, including recommendations and reimbursement decisions by national health authorities and early access programs. Commercial updates, such as regional partnerships and sales performance for IDEFIRIX in Europe, are part of this coverage.
Beyond clinical and commercial topics, the HNSBF news feed features information on collaborations in gene therapy where imlifidase is evaluated as a pre-treatment for AAV-based therapies, as well as financing transactions and corporate governance developments. For investors and observers interested in Hansa Biopharma’s progress, this page provides a centralized view of key press releases and company statements linked to the HNSBF symbol.
Hansa Biopharma has entered an agreement with Asklepios BioPharmaceutical to explore the use of imlifidase as a pre-treatment for gene therapy in Pompe disease. Hansa will receive a USD 5 million payment upon execution of the agreement, with AskBio holding an exclusive option for further development based on initial study results. Pompe disease affects 1 in 40,000 births and is caused by a deficiency in the GAA enzyme. This collaboration aims to address challenges posed by neutralizing antibodies against AAV vectors in gene therapies.
Hansa Biopharma will release its interim report for January-June 2021 on July 15, 2021, at 8:00 CET. A conference call detailing the interim results and business update will occur the same day at 14:00 CET. The call will be led by CEO Søren Tulstrup and CFO Donato Spota, available in English. Presentation slides will be accessible on the company's website. Interested parties can join via dial-in numbers for Sweden, the UK, and the U.S. The webcast link will also be provided. Additional events are scheduled through the year, including the William Blair Biotech Focus Conference.
Hansa Biopharma AB announced its 2020 Annual Report, highlighting significant achievements in pipeline development and market approval. The company received conditional approval for Idefirix® in the EU for kidney transplant patients, marking its first market entry. Additionally, an exclusive agreement with Sarepta Therapeutics for developing imlifidase for gene therapy was established. Despite COVID-19-related setbacks, enrollment for ongoing clinical trials resumed. Hansa aims to launch Idefirix® in select European markets and initiate a U.S. study for highly sensitized patients in 2021, with a BLA submission anticipated by 2023.
Hansa Biopharma announced the appointment of Magnus Korsgren, M.D., Ph.D., as Vice President and Head of Research and Development, effective April 1, 2021. Dr. Korsgren brings over 15 years of experience in drug development from companies like AstraZeneca and Novartis, focusing on immunology and transplant-related therapies. He will lead advancements in Hansa's pipeline, including its lead asset, imlifidase, which received conditional EU approval in August 2020 for kidney transplant desensitization. This strategic appointment aims to strengthen Hansa's position in the industry.
Hansa Biopharma will hold its 2020 Capital Markets Day on October 29 in Copenhagen. Scheduled for 13:30-17:30 CET (7:30am-11:30am EST), the event aims to showcase Hansa's evolution into a commercial biopharmaceutical entity. The focus will be on the company's antibody-cleaving enzyme platform, exploring its applications in autoimmunity and gene therapy beyond transplantation. While a limited number of attendees can participate in-person due to COVID-19, the event will be livestreamed for broader accessibility. Registrants will receive a detailed agenda later.